Quimigen Portugal > Human Apolipoprotein AI Protein
Human Apolipoprotein AI Protein
Brand : Aviva Systems Biology
Human ApolipoProtein AI Protein (OPMA04360)
| Datasheets/Manuals | Printable datasheet for OPMA04360 |
|---|
| Predicted Species Reactivity | Human |
|---|---|
| Product Format | Purified, Liquid |
| Host | High-density lipoprotein (HDL) from pooled Human plasma |
| :: | Buffer: 3M Guanidine hydrochloride, 10mM Tris, 5mM DTT, pH 8.0 Preservative: No Important Note: Centrifuge before opening to ensure complete recovery of vial contents. Warnings: All human source materials have tested negative for NHCV/NHIV nucleic acid test, HCV antigen; HBsAg, HBcAg, HIV1 Ag; and syphilis. No test guarantees a product to be non-infectious. Therefore, all material derived from human fluids or tissues sh |
| Reconstitution and Storage | Short-term store at 2 to 8C. Long term store at -20C. Avoid multiple freeze/thaw cycles. Storage of dialyzed Apo AI in PBS or TBS with 1mM EDTA and 0.1% Sodium Azide should be stored for up to 2 weeks at 2 to 8C. Storage of Apo |
| Purification | Purified |
| Purity | >99% pure (SDS-PAGE) Isolated by ultracentrifugal flotation between densities 1.063-1.21g/ml, lyophilized then subjected to repeated ethanol extraction. The precipitated protein was dried under nitrogen then dissolved in 6M guanidine hydrochloride -25 |
| Specificity | Apolipoprotein AI (Apo AI) |
| Application Info | Apo AI can be re-natured into PBS, TBS and other common buffers by dialysis using a membrane with a nominal molecular weight cut-off of 14,000 or less. This should be performed in a cold room. Each laboratory should determine an optimum working titer for |
| Application Data | Inactivation: Not applicable |
| Gene Symbol | APOA1 |
|---|---|
| Alias Symbols | HPALP2, apo(a) |
| NCBI Gene Id | 335 |
| Protein Name | Apolipoprotein A-I |
| Uniprot ID | P02647 |
| Protein Accession # | NP_000030.1 |
Protein interactions
| Name | # of Products |
|---|---|
| ABCA1 | 83 |
| APOA1 | 127 |
| APOA1BP | 38 |
| APOB | 76 |
| APOC1 | 39 |
| APOF | 38 |
| APOL1 | 29 |
| ATP5B | 75 |
| CD40LG | 130 |
| CETP | 41 |
| CFHR1 | 38 |
| CLEC4G | 91 |
| GPLD1 | 55 |
| HC | 29 |
| HPR | 80 |
| LBP | 79 |
| LCAT | 41 |
| MAP7D1 | 35 |
| MAPK6 | 386 |
| MIS12 | 149 |
| PCMT1 | 32 |
| PDE1A | 29 |
| PLTP | 55 |
| PON1 | 56 |
| SAA2 | 29 |
| SCARB1 | 51 |
| TNFRSF10C | 41 | <
| TOMM20 | 54 |
| TTR | 151 |
| UCHL5 | 365 |
Biological pathways
| Name | # of Products |
|---|---|
| Cdc42 protein signal transduction | 53 |
| Cholesterol efflux | 92 |
| Cholesterol homeostasis | 162 |
| Cholesterol import | 29 |
| G-protein coupled receptor signaling pathway | 315 |
| High-density lipoprotein particle assembly | 58 |
| High-density lipoprotein particle clearance | 64 |
| High-density lipoprotein particle remodeling | 84 |
| Negative regulation of cytokine secretion involved in immune response | 90 |
| Negative regulation of interleukin-1 beta secretion | 29 |
| Negative regulation of very-low-density lipoprotein particle remodeling | 45 |
| Phosphatidylcholine biosynthetic process | 45 |
| Phospholipid efflux | 83 |
| Platelet activation | 875 |
| Platelet degranulation | 443 |
| Positive regulation of cholesterol esterification | 75 |
| Positive regulation of hydrolase activity | 31 |
| Protein stabilization | 177 |
| Reverse cholesterol transport | 103 |
Biological process
| Name | # of Products |
|---|---|
| Adrenal gland development | 31 |
| Blood coagulation | 396 |
| Blood vessel endothelial cell migration | 9 |
| Cdc42 protein signal transduction | 5 |
| Cellular lipid metabolic process | 114 |
| Cholesterol biosynthetic process | 37 |
| Cholesterol efflux | 28 |
| Cholesterol homeostasis | 56 |
| Cholesterol import | 4 |
| Cholesterol metabolic process | 72 |
| Cholesterol transport | 16 |
| Endothelial cell proliferation | 15 |
| Glucocorticoid metabolic process | 6 |
| G-protein coupled receptor signaling pathway | 262 |
| High-density lipoprotein particle assembly | 8 |
| High-density lipoprotein particle clearance | 8 |
| High-density lipoprotein particle remodeling | 17 |
| Lipid metabolic process | 172 |
| Lipid storage | 19 |
| Lipoprotein biosynthetic process | 8 |
| Lipoprotein metabolic process | 40 |
| Negative regulation of cytokine secretion involved in immune response | 13 |
| Negative regulation of hydrolase activity | 8 |
| Negative regulation of interleukin-1 beta secretion | 2 |
| Negative regulation of very-low-density lipoprotein particle remodeling | 5 |
| Phosphatidylcholine biosynthetic process | 13 |
| Phospholipid efflux | 14 |
| Phospholipid metabolic process | 26 |
| Platelet activation | 202 |
| Platelet degranulation | 78 |
| Positive regulation of cholesterol esterification | 9 |
| Positive regulation of hydrolase activity | 4 |
| Positive regulation of transferase activity | 7 |
| Protein stabilization | 64 |
| Regulation of intestinal cholesterol absorption | 9 |
| Regulation of protein phosphorylation | 28 |
| Reverse cholesterol transport | 22 |
| Small molecule metabolic process | 825 |
| Steroid metabolic process | 76 |
| Transmembrane transport | 500 |
Cellular components
| Name | # of Products |
|---|---|
| Cytoplasmic vesicle | 253 |
| Endocytic vesicle | 34 |
| Endoplasmic reticulum lumen | 87 |
| Extracellular region | 1573 |
| Extracellular space | 884 |
| High-density lipoprotein particle | 22 |
| Plasma membrane | 2678 |
| Secretory granule | 77 |
| Spherical high-density lipoprotein particle | 9 |
| Very-low-density lipoprotein particl | 1 |
Protein function
| Name | # of Products |
|---|---|
| Apolipoprotein A-I receptor binding | 30 |
| Apolipoprotein receptor binding | 46 |
| Beta-amyloid binding | 111 |
| Cholesterol binding | 131 |
| Cholesterol transporter activity | 83 |
| Enzyme binding | 898 |
| High-density lipoprotein particle binding | 58 |
| High-density lipoprotein particle receptor binding | 46 |
| Identical protein binding | 1130 |
| Lipid transporter activity | 92 |
| Phosphatidylcholine-sterol O-acyltransferase activator activity | 61 |
| Phospholipid binding | 197 |
| Protein binding | 12191 |
Diseases
| Name | # of Products |
|---|---|
| Amyloidosis | 223 |
| Atherosclerosis | 77 |
| Disease mutation | 5332 |
| Neuropathy | 162 |
-
Apoa1 Antibody - N-terminal region (ARP54279_P050)Catalog #: ARP54279_P050Species Tested: RatApplication: WBFormat: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. -
APOA1 Antibody - N-terminal region (OAAB04428)Catalog #: OAAB04428Application: IHC-P,WBFormat: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. -
ApolipoProtein A1 ELISA Kit (Human) (OKIA00053)Catalog #: OKIA00053Application: ELISAKit Range: 15.6 ng/ml - 500 ng/mlSensitivity: 4.022 ng/mlFormat: In Solution -
ApoA1 Antibody (OAPB00855)Catalog #: OAPB00855Conjugation: UnconjugatedApplication: ELISA, IF, WBFormat: Liquid. ApoA1 Antibody is supplied in PBS containing 0.02% sodium azide. -
APOA1 Antibody - C-terminal region (OAEB03242)Catalog #: OAEB03242Application: ELISA|IHCFormat: Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.


